Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction

Aims In 2021, vericiguat was approved by the US Food and Drug Administration (FDA) and the European Commission (EC) for reducing cardiovascular mortality and heart failure (HF) hospitalizations in patients with HF with reduced ejection fraction (HFrEF) based on the Vericiguat Global Study in Subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jaewon, Lee, Chan Joo, Park, Jin Joo, Lee, Sang Eun, Kim, Min‐Seok, Cho, Hyun‐Jai, Choi, Jin‐Oh, Lee, Hae‐Young, Hwang, Kyung‐Kuk, Kim, Kye Hun, Yoo, Byung‐Su, Choi, Dong‐Ju, Baek, Sang Hong, Jeon, Eun‐Seok, Kim, Jae‐Joong, Cho, Myeong‐Chan, Chae, Shung Chull, Oh, Byung‐Hee, Kang, Seok‐Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934970/
https://www.ncbi.nlm.nih.gov/pubmed/35142095
http://dx.doi.org/10.1002/ehf2.13837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934970/
https://www.ncbi.nlm.nih.gov/pubmed/35142095
http://dx.doi.org/10.1002/ehf2.13837

Ejemplares similares